조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2024년10월
Oral Proteins and Peptides Market – Global Forecast To 2029
경구 단백질 및 펩타이드 시장 – 분자 (세마글루티드, 리나클로티드, 칼시토닌), 약물 클래스 (GLP-1 수용체 작용제, GEP, CGRP), 치료 영역 (당뇨병, 소화기 질환, 유전성 질환), 제형 (정제, 캡슐) – 2029년까지 세계 예측
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) – Global Forecast to 2029
| 페이지 수 | 319 |
| 도표 수 | 460 |
| 가격 | |
| Single User License | USD 4,950 |
| Multi User License | USD 6,650 |
| Corporate License | USD 8,150 |
| Enterprise License | USD 10.000 |
| 구성 | 영문조사보고서 |
Report Overview
The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029.
세계 경구 단백질 및 펩타이드 시장은 2024년부터 2029년까지의 예측 기간 동안 22.5%의 CAGR로 2024년 73억 8,000만 달러에서 2029년까지 203억 6,000만 달러에 이를 것으로 예측됩니다.
The growth of the oral proteins and peptides market has been significantly driven by its increasing demand of oral peptides for the treatment of chronic diseases such as diabetes and CNS disorders, increasing R&D investment by key players for the development and launch of innovative oral peptides and continuous advancements in drug delivery technologies. However, high development cost and the hurdles in formulation and stability are restraining market growth.
“The semaglutide molecule segment accounted for the largest share by molecule in 2023.”
In 2023, the semaglutide segment accounted for the largest share by molecule in the global oral proteins and peptides market. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes and obesity. Semaglutide works by enhancing insulin secretion in response to elevated blood glucose, reducing glucagon release (which raises blood sugar), and promoting a feeling of fullness after eating, which can help reduce food intake. Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes.
“The US has continued to dominate the oral proteins and peptides market during the forecast period of 2024-2029.”
The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals’ importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of oral proteins and peptides in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), Pfizer Inc. (US)
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of key Companies Profiled in the Report:
Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)
Research Coverage:
This research report categorizes the oral proteins and peptides market by molecule (Trofinetide, Semaglutide, Linaclotide, Voclosporin, Plecanatide, Calcitonin, and Others), by Drug Class (Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others), by Therapeutic Area (Genetic Disorder, Diabetes, Nephrology, Gastroenterology, CNS Disorders, Obesity & Overweight, and Others) by Formulation (Tablet, Capsules, and Oral Solution), by End User (Home Care Settings, Long-Term Care Facilities, Hospitals & Specialty Clinics) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.
Table of Contents
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 INCLUSIONS & EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 34
1.3.4 CURRENCY CONSIDERED 35
1.4 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
2.1.1 SECONDARY DATA 37
2.1.2 PRIMARY DATA 37
2.2 MARKET SIZE ESTIMATION 39
2.2.1 INSIGHTS FROM PRIMARIES 41
2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 41
2.3 MARKET GROWTH FORECAST 42
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44
2.5 STUDY ASSUMPTIONS 45
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW 51
4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023) 52
4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023 52
4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029 53
4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing burden of chronic diseases 55
5.2.1.2 Advancements in drug delivery technologies 56
5.2.1.3 Higher patient compliance and preference for oral route 56
5.2.1.4 Expanding therapeutic applications of oral proteins & peptides 57
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of drug development 57
5.2.2.2 Contraindication of oral proteins & peptides 57
5.2.2.3 Stringent regulatory approval process 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides 58
5.2.3.2 Growing demand for personalized medicine 59
5.2.4 CHALLENGES 59
5.2.4.1 Hurdles in formulation and stability 59
5.2.4.2 Availability of alternative therapies 60
5.3 ECOSYSTEM ANALYSIS 61
5.3.1 ROLE OF RAW MATERIAL VENDORS 61
5.3.2 ROLE OF PRODUCT PROVIDERS 62
5.3.3 ROLE OF END USERS 62
5.3.4 ROLE OF REGULATORY AUTHORITIES 62
5.4 VALUE CHAIN ANALYSIS 63
5.5 SUPPLY CHAIN ANALYSIS 65
5.6 PORTER’S FIVE FORCES ANALYSIS 66
5.6.1 THREAT OF NEW ENTRANTS 67
5.6.2 THREAT OF SUBSTITUTES 67
5.6.3 BARGAINING POWER OF SUPPLIERS 68
5.6.4 BARGAINING POWER OF BUYERS 68
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.7 KEY STAKEHOLDERS & BUYING CRITERIA 68
5.7.1 KEY STAKEHOLDERS 68
5.7.2 BUYING CRITERIA 69
5.8 PRICING ANALYSIS 71
5.8.1 PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS 71
5.8.2 PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION 72
5.9 REGULATORY LANDSCAPE 73
5.9.1 REGULATORY SCENARIO 73
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.11 TECHNOLOGY ANALYSIS 77
5.11.1 KEY TECHNOLOGIES 77
5.11.1.1 Transient permeation enhancer 77
5.11.1.2 Gastrointestinal permeation enhancement technology 78
5.11.1.3 Oral sCT (OSTORA) technology 78
5.11.2 COMPLEMENTARY TECHNOLOGIES 78
5.11.2.1 Peptelligence 78
5.11.2.2 ThioMatrix 78
5.11.2.3 Transferrin-based recombinant fusion protein 79
5.11.3 ADJACENT TECHNOLOGIES 79
5.11.3.1 Oramed and Orasome 79
5.11.3.2 Q-sphera 79
5.11.3.3 Nanoinclusion 79
5.11.3.4 Oleotec and Soctec 80
5.12 PIPELINE ANALYSIS 80
5.13 PATENT ANALYSIS 81
5.13.1 METHODOLOGY 81
5.13.2 INNOVATION AND PATENT APPLICATIONS 81
5.13.3 TOP APPLICANTS 81
5.14 KEY CONFERENCES & EVENTS, 2024–2025 83
5.15 INVESTMENT & FUNDING SCENARIO 84
5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET 85
6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE 87
6.1 INTRODUCTION 88
6.2 SEMAGLUTIDE 88
6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH 88
6.3 CALCITONIN 91
6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION 91
6.4 LINACLOTIDE 94
6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH 94
6.5 TROFINETIDE 96
6.5.1 FDA APPROVAL TO SUPPORT GROWTH 96
6.6 VOCLOSPORIN 99
6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION 99
6.7 PLECANATIDE 101
6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH 101
6.8 OTHER MOLECULES 103
7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS 107
7.1 INTRODUCTION 108
7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS 108
7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH 108
7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS 111
7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION 111
7.4 GUANYLATE CYCLASE-C AGONISTS 114
7.4.1 RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET 114
7.5 GLYCINE-PROLINE-GLUTAMATE 117
7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH 117
7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS 119
7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH 119
7.7 OTHER DRUG CLASSES 121
8 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA 125
8.1 INTRODUCTION 126
8.2 DIABETES 126
8.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION 126
8.3 CNS DISORDERS 130
8.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 130
8.4 GASTROENTEROLOGY 133
8.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH 133
8.5 GENETIC DISORDERS 136
8.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH 136
8.6 NEPHROLOGY 139
8.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET 139
8.7 OBESITY & OVERWEIGHT 141
8.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH 141
8.8 OTHER THERAPEUTIC AREAS 143
9 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION 146
9.1 INTRODUCTION 147
9.2 TABLETS 147
9.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH 147
9.3 CAPSULES 150
9.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET 150
9.4 ORAL SOLUTIONS 153
9.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH 153
10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER 156
10.1 INTRODUCTION 157
10.2 HOME CARE SETTINGS 157
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH 157
10.3 LONG-TERM CARE FACILITIES 160
10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH 160
10.4 HOSPITALS & SPECIALTY CLINICS 163
10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH 163
11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION 167
11.1 INTRODUCTION 168
11.2 NORTH AMERICA 168
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 169
11.2.2 US 173
11.2.2.1 US to hold large share of North American and global markets 173
11.2.3 CANADA 175
11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth 175
11.3 EUROPE 177
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 178
11.3.2 GERMANY 182
11.3.2.1 Germany to hold largest share of European market 182
11.3.3 UK 185
11.3.3.1 Strong focus on advancement of life sciences to support market growth 185
11.3.4 FRANCE 187
11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth 187
11.3.5 ITALY 190
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market 190
11.3.6 SPAIN 192
11.3.6.1 Initiatives associated with GLP-1 drugs to drive market 192
11.3.7 NETHERLANDS 195
11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth 195
11.3.8 REST OF EUROPE 197
11.4 ASIA PACIFIC 199
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 200
11.4.2 CHINA 203
11.4.2.1 Increasing R&D expenditure to drive market 203
11.4.3 JAPAN 206
11.4.3.1 Increasing prevalence of diabetes to drive market 206
11.4.4 INDIA 208
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth 208
11.4.5 AUSTRALIA 211
11.4.5.1 Rising access to GLP-1 drugs and government support to drive market 211
11.4.6 SOUTH KOREA 213
11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth 213
11.4.7 REST OF ASIA PACIFIC 216
11.5 LATIN AMERICA 218
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 218
11.5.2 BRAZIL 221
11.5.2.1 Brazil to hold largest market share in Latin America 221
11.5.3 MEXICO 224
11.5.3.1 Growing diabetes and obesity cases to support market growth 224
11.5.4 REST OF LATIN AMERICA 226
11.6 MIDDLE EAST 229
11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 229
11.6.2 GCC COUNTRIES 232
11.6.2.1 Saudi Arabia 235
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth 235
11.6.2.2 UAE 237
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to propel market 237
11.6.2.3 Rest of GCC countries 240
11.6.3 REST OF MIDDLE EAST 242
11.7 AFRICA 244
11.7.1 LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET 244
11.7.2 AFRICA: MACROECONOMIC OUTLOOK 244
12 COMPETITIVE LANDSCAPE 248
12.1 OVERVIEW 248
12.2 KEY STRATEGIES/RIGHT TO WIN 248
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES 249
12.3 REVENUE SHARE ANALYSIS 250
12.4 MARKET SHARE ANALYSIS 250
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 252
12.5.1 STARS 252
12.5.2 EMERGING LEADERS 252
12.5.3 PERVASIVE PLAYERS 253
12.5.4 PARTICIPANTS 253
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023 254
12.6.1 STARS 254
12.6.2 EMERGING LEADERS 254
12.6.3 PERVASIVE PLAYERS 254
12.6.4 PARTICIPANTS 254
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 256
12.6.5.1 Company Footprint 256
12.6.5.2 Molecule footprint 258
12.6.5.3 Formulation footprint 258
12.6.5.4 Therapeutic area footprint 259
12.6.5.5 Region footprint 260
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 262
12.7.1 PROGRESSIVE COMPANIES 262
12.7.2 RESPONSIVE COMPANIES 262
12.7.3 DYNAMIC COMPANIES 262
12.7.4 STARTING BLOCKS 262
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 264
12.7.5.1 Detailed list of key startups/SMEs 264
12.7.5.2 Competitive benchmarking of key startups/SMEs 265
12.8 VALUATION & FINANCIAL METRICS 266
12.8.1 FINANCIAL METRICS 266
12.8.2 COMPANY VALUATION 266
12.9 BRAND/PRODUCT COMPARISON 267
12.10 COMPETITIVE SCENARIO 268
12.10.1 PRODUCT APPROVALS 268
12.10.2 DEALS 269
12.10.3 EXPANSIONS 270
12.10.4 OTHER DEVELOPMENTS 270
13 COMPANY PROFILES 272
13.1 INTRODUCTION 272
13.2 KEY PLAYERS 272
13.2.1 NOVO NORDISK A/S 272
13.2.1.1 Business overview 272
13.2.1.2 Products offered 273
13.2.1.3 Recent developments 274
13.2.1.3.1 Product launches & approvals 274
13.2.1.3.2 Expansions 274
13.2.1.3.3 Other developments 275
13.2.1.4 MnM view 275
13.2.1.4.1 Right to win 275
13.2.1.4.2 Strategic choices 275
13.2.1.4.3 Weaknesses & competitive threats 275
13.2.2 ABBVIE INC. 276
13.2.2.1 Business overview 276
13.2.2.2 Products offered 277
13.2.2.3 Recent developments 278
13.2.2.3.1 Product approvals 278
13.2.2.4 MnM view 278
13.2.2.4.1 Right to win 278
13.2.2.4.2 Strategic choices 278
13.2.2.4.3 Weaknesses & competitive threats 279
13.2.3 PFIZER INC. 280
13.2.3.1 Business overview 280
13.2.3.2 Product pipeline 281
13.2.3.3 Recent developments 282
13.2.3.3.1 Product approvals 282
13.2.3.3.2 Deals 282
13.2.3.3.3 Other developments 283
13.2.3.4 MnM view 283
13.2.3.4.1 Right to win 283
13.2.3.4.2 Strategic choices 283
13.2.3.4.3 Weaknesses & competitive threats 283
13.2.4 BAUSCH HEALTH COMPANIES INC. 284
13.2.4.1 Business overview 284
13.2.4.2 Products offered 285
13.2.4.3 Recent developments 286
13.2.4.3.1 Product approvals 286
13.2.5 CHIESI FARMACEUTICI S.P.A. 287
13.2.5.1 Business overview 287
13.2.5.2 Products offered 288
13.2.5.3 Recent developments 288
13.2.5.3.1 Deals 288
13.2.6 ACADIA PHARMACEUTICALS INC. 289
13.2.6.1 Business overview 289
13.2.6.2 Products offered 290
13.2.6.3 Recent developments 290
13.2.6.3.1 Product approvals 290
13.2.7 AURINIA PHARMACEUTICALS INC. 291
13.2.7.1 Business overview 291
13.2.7.2 Products offered 292
13.2.7.3 Recent developments 292
13.2.7.3.1 Product approvals 292
13.2.8 MERCK & CO., INC. 293
13.2.8.1 Business overview 293
13.2.8.2 Product pipeline 294
13.2.8.3 Recent developments 295
13.2.8.3.1 Other developments 295
13.2.9 JOHNSON & JOHNSON SERVICES, INC. 296
13.2.9.1 Business overview 296
13.2.9.2 Product pipeline 297
13.2.9.3 Recent developments 298
13.2.9.3.1 Other developments 298
13.2.10 SWK HOLDINGS 299
13.2.10.1 Business overview 299
13.2.10.2 Product pipeline 300
13.2.10.3 Recent developments 300
13.2.10.3.1 Other developments 300
13.2.11 R-PHARM JSC 301
13.2.11.1 Business overview 301
13.2.11.2 Products in pipeline 301
13.2.12 ENTERA BIO LTD. 302
13.2.12.1 Business overview 302
13.2.12.2 Product pipeline 302
13.2.12.3 Recent developments 303
13.2.12.3.1 Deals 303
13.2.12.3.2 Other developments 303
13.2.13 PROXIMA CONCEPTS 304
13.2.13.1 Business overview 304
13.2.13.2 Products in pipeline 304
13.3 OTHER PLAYERS 305
13.3.1 ASTRAZENECA PLC 305
13.3.2 REGOR THERAPEUTICS GROUP 305
13.3.3 TERNS PHARMACEUTICALS, INC. 306
13.3.4 STRUCTURE THERAPEUTICS 306
13.3.5 VIKING THERAPEUTICS 307
13.3.6 PROTAGONIST THERAPEUTICS INC. 307
13.3.7 RANI THERAPEUTICS 308
13.3.8 CARMOT THERAPEUTICS, INC. 308
13.3.9 ZEALAND PHARMA 309
13.3.10 SCIWIND BIOSCIENCES CO., LTD. 309
13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 310
14 APPENDIX 311
14.1 DISCUSSION GUIDE 311
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 315
14.3 CUSTOMIZATION OPTIONS 317
14.4 RELATED REPORTS 317
14.5 AUTHOR DETAILS 318
LIST OF TABLES
TABLE 1 ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS 55
TABLE 2 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS 61
TABLE 3 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS 62
TABLE 4 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS 62
TABLE 5 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES 63
TABLE 6 ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS 66
TABLE 7 BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER 70
TABLE 8 PRICING ANALYSIS, BY PRODUCT, 2024 71
TABLE 9 PRICING ANALYSIS, BY COUNTRY AND REGION (USD), 2024 72
TABLE 10 REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET 73
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 15 ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF AUGUST 2024) 80
TABLE 16 ORAL PROTEINS & PEPTIDES MARKET: TOP 20 PATENT OWNERS, 2014–2024 82
TABLE 17 INDICATIVE LIST OF PATENTS IN ORAL PROTEINS & PEPTIDES MARKET,
2022–2024 83
TABLE 18 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF
CONFERENCES & EVENTS 83
TABLE 19 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022–2029 (USD MILLION) 88
TABLE 20 SEMAGLUTIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 89
TABLE 21 NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 89
TABLE 22 EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 23 ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 24 LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 90
TABLE 25 MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 90
TABLE 26 GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 91
TABLE 27 CALCITONIN MARKET, BY REGION, 2022–2029 (USD MILLION) 91
TABLE 28 NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 29 EUROPE: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 30 ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 31 LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 32 MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2022–2029 (USD MILLION) 93
TABLE 33 GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 34 LINACLOTIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 94
TABLE 35 NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 94
TABLE 36 EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 37 ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 38 LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 39 MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 40 GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 96
TABLE 41 TROFINETIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 97
TABLE 42 NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 97
TABLE 43 EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 44 ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 45 LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 46 MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 98
TABLE 47 GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 99
TABLE 48 VOCLOSPORIN MARKET, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 49 NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 100
TABLE 50 EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 51 ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 52 PLECANATIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 101
TABLE 53 NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 101
TABLE 54 EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 55 ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 56 LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 57 MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 58 GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 103
TABLE 59 OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION,
2022–2029 (USD MILLION) 104
TABLE 60 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 61 EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 62 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 63 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 64 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY REGION, 2022–2029 (USD MILLION) 106
TABLE 65 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 66 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 108
TABLE 67 GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 68 NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 69 EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 70 ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 110
TABLE 71 LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 110
TABLE 72 MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION,
2022–2029 (USD MILLION) 111
TABLE 73 GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 111
TABLE 74 CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 75 NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 76 EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 77 ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 113
TABLE 78 LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 113
TABLE 79 MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION,
2022–2029 (USD MILLION) 113
TABLE 80 GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 114
TABLE 81 GC-C AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 82 NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 83 EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 84 ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 85 LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 116
TABLE 86 MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2022–2029 (USD MILLION) 116
TABLE 87 GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 116
TABLE 88 GPE MARKET, BY REGION, 2022–2029 (USD MILLION) 117
TABLE 89 NORTH AMERICA: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 90 EUROPE: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 91 ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 92 LATIN AMERICA: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 93 MIDDLE EAST: GPE MARKET, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 94 GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 95 CNI MARKET, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 96 NORTH AMERICA: CNI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 97 EUROPE: CNI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 98 ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 99 OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY REGION, 2022–2029 (USD MILLION) 122
TABLE 100 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 101 EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 102 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 103 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 104 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY REGION, 2022–2029 (USD MILLION) 123
TABLE 105 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 106 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 126
TABLE 107 ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION,
2022–2029 (USD MILLION) 127
TABLE 108 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 109 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 110 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 111 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 112 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 113 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 114 ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION,
2022–2029 (USD MILLION) 130
TABLE 115 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 116 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 117 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 118 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 119 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 120 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 121 ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,
BY REGION, 2022–2029 (USD MILLION) 133
TABLE 122 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 123 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 124 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 125 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 126 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 127 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 128 ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022–2029 (USD MILLION) 136
TABLE 129 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 130 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 131 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 132 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 133 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022–2029 (USD MILLION) 138
TABLE 134 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 135 ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION,
2022–2029 (USD MILLION) 139
TABLE 136 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 137 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 138 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 139 ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 140 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 141 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT,
BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 142 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 143 ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2022–2029 (USD MILLION) 143
TABLE 144 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 145 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 146 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 147 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 148 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 149 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 150 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 147
TABLE 151 ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION,
2022–2029 (USD MILLION) 148
TABLE 152 NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 153 EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 148
TABLE 154 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 155 LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 156 MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 157 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 158 ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION,
2022–2029 (USD MILLION) 150
TABLE 159 NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 160 EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 151
TABLE 161 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 151
TABLE 162 LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 163 MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 164 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 165 ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION,
2022–2029 (USD MILLION) 153
TABLE 166 NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 167 EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 154
TABLE 168 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 169 LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 170 MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 171 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 172 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022–2029 (USD MILLION) 157
TABLE 173 ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS,
BY REGION, 2022–2029 (USD MILLION) 158
TABLE 174 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 175 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 176 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME
CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 177 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 178 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 179 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 180 ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES,
BY REGION, 2022–2029 (USD MILLION) 161
TABLE 181 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 182 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 183 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 184 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 185 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 186 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 187 ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS,
BY REGION, 2022–2029 (USD MILLION) 164
TABLE 188 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 189 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 190 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 191 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 192 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION) 165
TABLE 193 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 194 ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 168
TABLE 195 NORTH AMERICA: MACROECONOMIC OUTLOOK 169
TABLE 196 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 170
TABLE 197 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 171
TABLE 198 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 171
TABLE 199 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 172
TABLE 200 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION) 172
TABLE 201 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 172
TABLE 202 US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 173
TABLE 203 US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 173
TABLE 204 US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 174
TABLE 205 US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 174
TABLE 206 US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 174
TABLE 207 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 175
TABLE 208 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 176
TABLE 209 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 176
TABLE 210 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 177
TABLE 211 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 177
TABLE 212 EUROPE: MACROECONOMIC OUTLOOK 178
TABLE 213 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 180
TABLE 214 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 180
TABLE 215 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 181
TABLE 216 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 181
TABLE 217 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 182
TABLE 218 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 182
TABLE 219 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 183
TABLE 220 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 183
TABLE 221 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 184
TABLE 222 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 184
TABLE 223 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 184
TABLE 224 UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 185
TABLE 225 UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 186
TABLE 226 UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 186
TABLE 227 UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 187
TABLE 228 UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 187
TABLE 229 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 188
TABLE 230 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 188
TABLE 231 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 189
TABLE 232 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 189
TABLE 233 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 189
TABLE 234 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 190
TABLE 235 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 191
TABLE 236 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 191
TABLE 237 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 192
TABLE 238 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 192
TABLE 239 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 193
TABLE 240 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 193
TABLE 241 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 194
TABLE 242 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 194
TABLE 243 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 194
TABLE 244 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 195
TABLE 245 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 195
TABLE 246 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 196
TABLE 247 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 196
TABLE 248 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 196
TABLE 249 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 197
TABLE 250 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 198
TABLE 251 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 198
TABLE 252 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022–2029 (USD MILLION) 199
TABLE 253 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 199
TABLE 254 ASIA PACIFIC: MACROECONOMIC OUTLOOK 200
TABLE 255 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 201
TABLE 256 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 201
TABLE 257 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 202
TABLE 258 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 202
TABLE 259 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 203
TABLE 260 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 203
TABLE 261 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 204
TABLE 262 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 204
TABLE 263 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 205
TABLE 264 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 205
TABLE 265 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 205
TABLE 266 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 206
TABLE 267 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 207
TABLE 268 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 207
TABLE 269 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 208
TABLE 270 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 208
TABLE 271 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 209
TABLE 272 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 209
TABLE 273 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 210
TABLE 274 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 210
TABLE 275 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 210
TABLE 276 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 211
TABLE 277 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 212
TABLE 278 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 212
TABLE 279 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 213
TABLE 280 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 213
TABLE 281 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 214
TABLE 282 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 214
TABLE 283 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 215
TABLE 284 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 215
TABLE 285 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 215
TABLE 286 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,
BY MOLECULE, 2022–2029 (USD MILLION) 216
TABLE 287 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,
BY DRUG CLASS, 2022–2029 (USD MILLION) 216
TABLE 288 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,
BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 217
TABLE 289 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,
BY FORMULATION, 2022–2029 (USD MILLION) 217
TABLE 290 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2022–2029 (USD MILLION) 217
TABLE 291 LATIN AMERICA: MACROECONOMIC OUTLOOK 218
TABLE 292 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 219
TABLE 293 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 219
TABLE 294 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 220
TABLE 295 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 220
TABLE 296 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 221
TABLE 297 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 221
TABLE 298 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 222
TABLE 299 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 222
TABLE 300 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 223
TABLE 301 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 223
TABLE 302 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 223
TABLE 303 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 224
TABLE 304 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 225
TABLE 305 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 225
TABLE 306 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 226
TABLE 307 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 226
TABLE 308 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY MOLECULE, 2022–2029 (USD MILLION) 227
TABLE 309 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY DRUG CLASS, 2022–2029 (USD MILLION) 227
TABLE 310 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 228
TABLE 311 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY FORMULATION, 2022–2029 (USD MILLION) 228
TABLE 312 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2022–2029 (USD MILLION) 228
TABLE 313 MIDDLE EAST: MACROECONOMIC OUTLOOK 229
TABLE 314 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 230
TABLE 315 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 230
TABLE 316 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 231
TABLE 317 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 231
TABLE 318 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 232
TABLE 319 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 232
TABLE 320 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY REGION,
2022–2029 (USD MILLION) 232
TABLE 321 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 233
TABLE 322 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 233
TABLE 323 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 234
TABLE 324 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 234
TABLE 325 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 234
TABLE 326 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 235
TABLE 327 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 236
TABLE 328 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 236
TABLE 329 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 237
TABLE 330 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 237
TABLE 331 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 238
TABLE 332 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 238
TABLE 333 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 239
TABLE 334 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 239
TABLE 335 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 239
TABLE 336 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY MOLECULE, 2022–2029 (USD MILLION) 240
TABLE 337 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY DRUG CLASS, 2022–2029 (USD MILLION) 240
TABLE 338 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 241
TABLE 339 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY FORMULATION, 2022–2029 (USD MILLION) 241
TABLE 340 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2022–2029 (USD MILLION) 241
TABLE 341 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,
BY MOLECULE, 2022–2029 (USD MILLION) 242
TABLE 342 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,
BY DRUG CLASS, 2022–2029 (USD MILLION) 242
TABLE 343 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,
BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 243
TABLE 344 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,
BY FORMULATION, 2022–2029 (USD MILLION) 243
TABLE 345 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2022–2029 (USD MILLION) 243
TABLE 346 AFRICA: MACROECONOMIC OUTLOOK 245
TABLE 347 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2022–2029 (USD MILLION) 245
TABLE 348 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2022–2029 (USD MILLION) 246
TABLE 349 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 246
TABLE 350 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2022–2029 (USD MILLION) 247
TABLE 351 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2022–2029 (USD MILLION) 247
TABLE 352 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ORAL
PROTEINS & PEPTIDES MARKET 249
TABLE 353 ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION 251
TABLE 354 ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS) 258
TABLE 355 ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS) 258
TABLE 356 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT
(KEY PLAYERS) 259
TABLE 357 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT
(PLAYERS WITH PRODUCTS IN PIPELINE) 259
TABLE 358 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS) 260
TABLE 359 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT
(PLAYERS WITH PRODUCTS IN PIPELINE) 261
TABLE 360 ORAL PROTEINS & PEPTIDES MARKET: KEY STARTUPS/SMES 264
TABLE 361 ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS 265
TABLE 362 ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS,
JANUARY 2021– AUGUST 2024 268
TABLE 363 ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021–AUGUST 2024 269
TABLE 364 ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS, JANUARY 2021–
AUGUST 2024 270
TABLE 365 ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS,
JANUARY 2021– AUGUST 2024 270
TABLE 366 NOVO NORDISK: COMPANY OVERVIEW 272
TABLE 367 NOVO NORDISK: PRODUCTS OFFERED 273
TABLE 368 NOVO NORDISK: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–
AUGUST 2024 274
TABLE 369 NOVO NORDISK: EXPANSIONS, JANUARY 2021– AUGUST 2024 274
TABLE 370 NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021– AUGUST 2024 275
TABLE 371 ABBVIE: COMPANY OVERVIEW 276
TABLE 372 ABBVIE: PRODUCTS OFFERED 277
TABLE 373 ABBVIE: PRODUCT APPROVALS, JANUARY 2021– AUGUST 2024 278
TABLE 374 PFIZER: COMPANY OVERVIEW 280
TABLE 375 PFIZER: PRODUCT PIPELINE 281
TABLE 376 PFIZER: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024 282
TABLE 377 PFIZER: DEALS, JANUARY 2021–AUGUST 2024 282
TABLE 378 PFIZER: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024 283
TABLE 379 BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW 284
TABLE 380 BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED 285
TABLE 381 BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS, JANUARY 2021–
AUGUST 2024 286
TABLE 382 CHIESI FARMACEUTICI: COMPANY OVERVIEW 287
TABLE 383 CHIESI FARMACEUTICI: PRODUCTS OFFERED 288
TABLE 384 CHIESI FARMACEUTICI: DEALS, JANUARY 2021–AUGUST 2024 288
TABLE 385 ACADIA PHARMACEUTICALS: COMPANY OVERVIEW 289
TABLE 386 ACADIA PHARMACEUTICALS: PRODUCTS OFFERED 290
TABLE 387 ACADIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–
AUGUST 2024 290
TABLE 388 AURINIA PHARMACEUTICALS: COMPANY OVERVIEW 291
TABLE 389 AURINIA PHARMACEUTICALS: PRODUCTS OFFERED 292
TABLE 390 AURINIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–
AUGUST 2024 292
TABLE 391 MERCK & CO.: COMPANY OVERVIEW 293
TABLE 392 MERCK & CO.: PRODUCT PIPELINE 294
TABLE 393 MERCK & CO.: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024 295
TABLE 394 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW 296
TABLE 395 JOHNSON & JOHNSON SERVICES: PRODUCT PIPELINE 297
TABLE 396 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2021– AUGUST 2024 298
TABLE 397 SWK HOLDINGS: COMPANY OVERVIEW 299
TABLE 398 SWK HOLDINGS: PRODUCT PIPELINE 300
TABLE 399 SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024 300
TABLE 400 R-PHARM JSC: COMPANY OVERVIEW 301
TABLE 401 R-PHARM JSC: PRODUCTS IN PIPELINE 301
TABLE 402 ENTERA BIO: COMPANY OVERVIEW 302
TABLE 403 ENTERA BIO: PRODUCT PIPELINE 302
TABLE 404 ENTERA BIO: DEALS, JANUARY 2021–AUGUST 2024 303
TABLE 405 ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024 303
TABLE 406 PROXIMA CONCEPTS: COMPANY OVERVIEW 304
TABLE 407 PROXIMA CONCEPTS: PRODUCTS IN PIPELINE 304
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 36
FIGURE 2 BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023 39
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023 40
FIGURE 5 MARKET VALIDATION FROM PRIMARY EXPERTS 41
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 41
FIGURE 7 CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2024–2029 43
FIGURE 8 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET 43
FIGURE 9 DATA TRIANGULATION METHODOLOGY 44
FIGURE 10 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2024 VS. 2029 (USD MILLION) 46
FIGURE 11 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS,
2024 VS. 2029 (USD MILLION) 47
FIGURE 12 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA,
2024 VS. 2029 (USD MILLION) 47
FIGURE 13 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION,
2024 VS. 2029 (USD MILLION) 48
FIGURE 14 ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 49
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET 50
FIGURE 16 INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS
TO DRIVE MARKET GROWTH 51
FIGURE 17 TABLETS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN
MARKET IN 2023 52
FIGURE 18 DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 52
FIGURE 19 HOME CARE SETTINGS TO DOMINATE MARKET TILL 2029 53
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53
FIGURE 21 ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 54
FIGURE 22 ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS 61
FIGURE 23 ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS 64
FIGURE 24 ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS 66
FIGURE 25 ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS 67
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF ORAL PROTEINS & PEPTIDES 68
FIGURE 27 KEY BUYING CRITERIA FOR END USERS 69
FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
FIGURE 29 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024 81
FIGURE 30 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS,
2014–2024 82
FIGURE 31 ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO 84
FIGURE 32 NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT 170
FIGURE 33 EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT 179
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES
MARKET, 2021–2023 (USD MILLION) 250
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES (2023) 251
FIGURE 36 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 253
FIGURE 37 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023 255
FIGURE 38 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS) 256
FIGURE 39 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 257
FIGURE 40 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 263
FIGURE 41 EV/EBITDA OF KEY VENDORS 266
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 266
FIGURE 43 ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 267
FIGURE 44 NOVO NORDISK: COMPANY SNAPSHOT 273
FIGURE 45 ABBVIE: COMPANY SNAPSHOT 277
FIGURE 46 PFIZER: COMPANY SNAPSHOT 281
FIGURE 47 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT 285
FIGURE 48 CHIESI FARMACEUTICI: COMPANY SNAPSHOT 287
FIGURE 49 ACADIA PHARMACEUTICALS: COMPANY SNAPSHOT 289
FIGURE 50 AURINIA PHARMACEUTICALS: COMPANY SNAPSHOT 291
FIGURE 51 MERCK & CO.: COMPANY SNAPSHOT 294
FIGURE 52 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT 297
FIGURE 53 SWK HOLDINGS: COMPANY SNAPSHOT 299
